Bliss GVS Pharma Ltd Share Price Today - Bliss GVS Pharma Ltd Stock Price Live NSE/BSE

Bliss GVS Pharma Ltd

NSE: BLISSGVS BSE: 506197

₹216.26

(-3.03%)

Fri, 13 Mar 2026, 03:37 am

MTF 5xInvest in Bliss GVS Pharma Ltd with 5x Leverage Buy with MTF

Market Cap23.56B

PE Ratio21.26

Dividend0.45

Health Technology

Pharmaceuticals: Major

24.5K

Bliss GVS Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
2214.69
Net Profit
90.26
P/B
1.18
Sector P/E
32.90
P/E
14.69
EV/EBITDA
6.82
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.89
ROCE (Industry)
16.43
RONW (Industry)
14.36
ROE
8.95
ROCE
12.09
Debt/Equity
0.09
EPS (TTM)
10.46
Dividend Yield
0.24
Book Value
107.04
Interest Cover
16.47

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are thoroughly covered by earnings (10.3x coverage).
Bliss GVS Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Bliss GVS Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Bliss GVS Pharma is profitable, therefore cash runway is not a concern.

Cons

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Bliss GVS Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
High level of physical assets or inventory.
Shibroor's remuneration is higher than average for companies of similar size in India.
Bliss GVS Pharma is not covered by any analysts.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	35.36	35.39	35.44	35.29	35.10
FII	14.54	13.27	12.65	13.18	13.51
DII	5.78	5.98	6.54	6.55	6.55
Public	44.32	45.36	45.36	44.98	44.84
Government	0	0	0	0	0

Technical Analysis

RSI

50.70

MACD

5.57

50 DMA

192.04

200 DMA

164.98

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	362.52	284.98	248.51	207.44	170.97	129.90	52.36
Fibonacci	284.98	255.36	237.06	207.44	177.82	159.52	129.90
Camarilla	233.37	226.27	219.16	207.44	204.94	197.83	190.73

Pivots Level: Classic

+155.08

362.52

+77.54

284.98

+41.08

248.51

207.44

Pivot Point

LTP: 209.20

-36.46

170.97

-77.54

129.90

-155.08

52.36

Moving Average

SMAEMA

Period

Value

10-EMA
214.32
20-EMA
211.63
30-EMA
206.54
50-EMA
197.17
100-EMA
182.77
200-EMA
168.37

Announcement Date	Purpose	Action	Ex Date
10 Feb 2026	board-meetings	Quarterly Results, Interim Dividend
10 Feb 2026	dividend	₹0.50 Dividend /Share	18 Feb 2026
18 Jan 2026	dividend	Interim Dividend - Re 0.50 Per Share	18 Feb 2026
06 Nov 2025	board-meetings	Quarterly Results
24 Jun 2025	dividend	Final Dividend - Rs. - 0.5	24 Jul 2025
12 May 2025	agm
12 May 2025	dividend	₹0.50 Dividend /Share	24 Jul 2025
18 Jun 2024	dividend	Annual General Meeting/Dividend - Rs 0.50 Per Share	19 Jul 2024
02 May 2024	agm
02 May 2024	dividend	₹0.50 Dividend /Share	19 Jul 2024

Bliss GVS Pharma Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Lupin Ltd

Divis Laboratories Ltd

Bliss GVS Pharma Ltd About

Bliss GVS Pharma is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company is one of among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1984

Headquarters

CEO

Nandkumar Kashinath Chodankar

Employees

Contact

Website

http://www.blissgvs.com

cs@blissgvs.com; info@blissgvs.com

Phone

91-22-42160000

Location

102 Hyde Park Sakivihar Road, Andheri East, Mumbai, Maharashtra, 400072

Year	History
2012	Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited
2013	Bliss GVS Pharma Ltd recommended a dividend of 40% Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India.
2014	Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list Bliss GVS Wins - Outstanding Exports Award.
2015	Bliss GVS Pharma wins Healthcare Services contract in Kenya
2016	Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.

Client Name	Order Side	QTY	Avg Price	Date
MANSUKH SECURITIES & FINANCE LIMITED	Buy	620900	220.81	24 Feb 2026
MANSUKH SECURITIES & FINANCE LIMITED	Sell	620900	216.22	24 Feb 2026
QE SECURITIES LLP	Buy	583870	234.28	17 Feb 2026
HRTI PRIVATE LIMITED	Buy	959323	232.87	17 Feb 2026
HRTI PRIVATE LIMITED	Sell	906202	232.64	17 Feb 2026
QE SECURITIES LLP	Sell	589185	232.56	17 Feb 2026
HRTI PRIVATE LIMITED	Buy	593004	212	11 Feb 2026
HRTI PRIVATE LIMITED	Sell	701637	211	11 Feb 2026
NIVL LEARNING EDUCATION PRIVATE LIMITED	Buy	542901	213	11 Feb 2026
NIVL LEARNING EDUCATION PRIVATE LIMITED	Sell	542901	213	11 Feb 2026

Bliss GVS Pharma Ltd News

Bliss GVS Pharma denies stake sale speculation

Bliss GVS Pharma clarifies that media reports about potential stake acquisition by Anupam Rasayan are speculative and not based on official communication.

13 Feb 2026

stocks

Bliss GVS Pharma Q3FY26 Results & Interim Dividend

Bliss GVS Pharma reported Q3FY26 standalone net profit of ₹1,860.71 lakh vs ₹2,105.25 lakh YoY. Board declared 50% interim dividend of ₹0.50 per share with February 18, 2026 record date.

10 Feb 2026

co actions results

Bliss GVS Pharma Sets Up Congo Subsidiary

Bliss GVS Pharma Limited announces incorporation of wholly owned subsidiary THERALIFE PHARMA RDC PRIVATE LIMITED in Democratic Republic of Congo through its Singapore unit.

27 Jan 2026

stocks

Bliss GVS Pharma Appoints CEO as Managing Director

Bliss GVS Pharma's board approves appointment of CEO S.N. Kamath as Managing Director for three years, subject to shareholder approval through postal ballot.

23 Dec 2025

stocks

Bliss GVS Pharma Allots 66,380 Equity Shares Under Employee Stock Option Plan

Bliss GVS Pharma's ESOP Allotment Committee approved the allotment of 66,380 equity shares of Re. 1/- each to eligible employees who exercised stock options under the company's 2019 Employee Stock Option Plan at Rs. 43/- per share. The allotment increases the company's total issued share capital to 10,57,88,972 equity shares aggregating Rs. 10,57,88,972/-, with the newly issued shares carrying a 6-month lock-in period until June 09, 2026.

09 Dec 2025

corporate action

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800